Unknown PHASE1 INTERVENTIONAL 1-arm NCT02956551

Personalized DC Vaccine for Lung Cancer (SKLB1608)

Neoantigen-primed DC Vaccine Therapy for Refractory Non-small Cell Lung Cancer

Sponsor: Sichuan University

Conditions Carcinoma, Non-Small-Cell Lung

Interventions DC vaccine

Updated 6 times since 2017 Last updated: May 29, 2018 Started: Nov 30, 2016 Primary completion: Dec 31, 2019 Completion: Jun 1, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Carcinoma, Non-Small-Cell Lung and is currently ongoing. Sichuan University leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jul 2020 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jun 2018 — Jul 2020 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sichuan University

Data source: Sichuan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China